The Fort Worth Press - Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

USD -
AED 3.672504
AFN 66.000368
ALL 81.003771
AMD 364.66866
AOA 918.000367
ARS 1485.503978
AUD 1.430206
AWG 1.8
AZN 1.70397
BAM 1.695315
BBD 2.008061
BDT 123.113596
BHD 0.375937
BIF 2958.60963
BMD 1
BND 1.279591
BOB 11.838946
BRL 5.080504
BSD 0.997009
BTN 95.046158
BWP 13.594244
BYN 2.900273
BYR 19600
BZD 2.005201
CAD 1.40195
CDF 2275.000362
CHF 0.807714
CLF 0.023563
CLP 930.403912
CNY 6.751304
CNH 6.753015
COP 3101.200537
CRC 452.823647
CUC 1
CUP 26.5
CVE 95.579248
CZK 21.012104
DJF 177.540849
DKK 6.48427
DOP 57.8425
DZD 132.884324
EGP 51.156763
ERN 15
ETB 159.322411
EUR 0.866804
FJD 2.21395
FKP 0.741868
GBP 0.741702
GEL 2.61504
GGP 0.741868
GHS 11.655181
GIP 0.741868
GMD 73.503851
GNF 8752.221211
GTQ 7.60716
GYD 208.555454
HKD 7.842204
HNL 26.714341
HRK 6.534304
HTG 130.360161
HUF 316.550388
IDR 18029
ILS 3.06295
IMP 0.741868
INR 95.390504
IQD 1306.115373
IRR 1375125.000352
ISK 123.140386
JEP 0.741868
JMD 157.838166
JOD 0.70904
JPY 157.39504
KES 128.964591
KGS 87.450384
KHR 4034.152473
KMF 427.00035
KRW 1442.940383
KWD 0.30914
KYD 0.830841
KZT 472.43098
LAK 22578.771725
LBP 89284.705067
LKR 334.694231
LRD 179.95926
LSL 16.490877
LTL 2.95274
LVL 0.60489
LYD 6.378884
MAD 9.313657
MDL 17.422962
MGA 4263.858189
MKD 53.330733
MMK 2099.556709
MNT 3594.538358
MOP 8.054349
MRU 40.069345
MUR 47.000345
MVR 15.460378
MWK 1728.773892
MXN 17.347104
MYR 4.085204
MZN 63.910377
NAD 16.490877
NGN 1364.360377
NIO 36.692238
NOK 9.471104
NPR 152.073853
NZD 1.700247
OMR 0.384553
PAB 0.997009
PEN 3.378841
PGK 4.464092
PHP 61.255038
PKR 276.891432
PLN 3.73795
PYG 5944.610584
QAR 3.644606
RON 4.548604
RSD 101.755298
RUB 79.263208
RWF 1463.615481
SAR 3.744926
SBD 8.081105
SCR 13.507563
SDG 600.000339
SEK 9.522704
SGD 1.282604
SLE 24.703667
SOS 569.756859
SRD 37.781504
STD 20697.981008
STN 21.236944
SVC 8.723616
SZL 16.488536
THB 33.525038
TJS 9.202271
TMT 3.51
TND 2.930958
TRY 47.512504
TTD 6.769818
TWD 32.309104
TZS 2641.52906
UAH 44.499112
UGX 3743.769774
UYU 40.116153
UZS 11934.295497
VES 745.696404
VND 26300.5
VUV 118.689846
WST 2.734491
XAF 568.592727
XAG 0.017363
XAU 0.000247
XCD 2.70255
XCG 1.796819
XDR 0.707147
XOF 568.592727
XPF 103.376241
YER 238.303589
ZAR 16.55773
ZMK 9001.203584
ZMW 18.728384
ZWL 321.999592
  • CMSC

    0.0300

    21.84

    +0.14%

  • BCC

    1.0000

    76.38

    +1.31%

  • RBGPF

    0.0000

    69.21

    0%

  • BCE

    -0.0200

    21.68

    -0.09%

  • CMSD

    0.0900

    22.11

    +0.41%

  • JRI

    0.0900

    12.96

    +0.69%

  • RYCEF

    -0.3100

    19.55

    -1.59%

  • NGG

    -0.4200

    79.97

    -0.53%

  • VOD

    -0.3600

    15.78

    -2.28%

  • RIO

    -0.3300

    96.85

    -0.34%

  • RELX

    -1.1900

    35.42

    -3.36%

  • GSK

    -0.3800

    51.69

    -0.74%

  • BTI

    -1.0400

    60.65

    -1.71%

  • AZN

    -1.7000

    169.64

    -1%

  • BP

    1.0000

    45.22

    +2.21%

Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / May 1, 2026 / RedChip Companies will air interviews with Anixia Biosciences, Inc. (NASDAQ:ANIX) and OwlTing Group (NASDAQ:OWLS), the operating brand of OBOOK Holdings Inc., on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Text size:

Access the interviews in their entirety at:

Dr. Amit Kumar, Chairman & CEO of Anixa Biosciences, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's innovative immunotherapy pipeline, led by its breast cancer vaccine targeting alpha-lactalbumin, a protein associated with most forms of breast cancer, including triple-negative breast cancer. Dr. Kumar highlights the vaccine's successful Phase 1 results demonstrating strong safety and immune response, supporting advancement toward Phase 2 trials. He emphasizes the program's long-term vision as both a therapeutic and preventative solution with the potential to significantly reduce or eliminate breast cancer incidence globally. Dr. Kumar also discusses the company's strategic collaboration with the Cleveland Clinic and funding support from the U.S. Department of Defense, which validate the underlying science and accelerate development. In addition, he outlines Anixa's broader oncology platform, including its CAR-T therapy for ovarian cancer, which has shown promising survival benefits in heavily pretreated patients.

Darren Wang, Founder, Chairman, and CEO of OwlTing, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how the company is building enterprise-grade global payments and settlement infrastructure designed for the growing stablecoin economy. Wang highlights OwlTing's compliance-first OwlPay platform, which enables regulated fiat and stablecoin transactions across multiple blockchains and payment networks, including Visa and Circle, and explains how the company's expanding global licenses and institutional partnerships are creating a durable regulatory moat. OwlTing's extensive global licensing footprint includes over 40 U.S. Money Transmitter Licenses (or equivalent), VASP registration in the European Union, and a Banking API License in Japan. Wang also outlines OwlTing's accelerating transaction growth, rising Gross Payment Volume, and transition toward scalable monetization as enterprises move from pilot programs to full production deployment, positioning OwlTing as a foundational payment infrastructure provider in the evolving market for global commerce.

ANIX and OWLS are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

About OwlTing Group
OwlTing Group (NASDAQ:OWLS) is the operating brand of OBOOK Holdings Inc., a global fintech company founded in Taiwan, with subsidiaries in the United States, Japan, Poland, Singapore, Hong Kong, Thailand, and Malaysia. The Company operates a diversified ecosystem across payments, hospitality, and e-commerce. In 2026, OwlTing was named to the Financial Times and Statista "High-Growth Companies Asia-Pacific 2026" list, ranking No. 226 among the top 500 fastest-growing companies in the region with a 42% CAGR. In 2025, OwlTing was ranked among the top 2 global players for the "Enterprise & B2B" category in the digital currency sector by CB Insights statistics. The Company's mission is to use distributed ledger technology to provide businesses with more reliable and transparent data management, to reinvent the global flow of funds for businesses and consumers, and to lead the digital transformation of business operations. To this end, the Company introduced OwlPay, a Web2 and Web3 hybrid payment solution, to empower global businesses to operate confidently in the expanding digital currency economy. For more information, visit https://www.owlting.com/portal/?lang=en.

About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

Sign Up for RedChat
RedChat™ is an AI-powered investment research assistant designed to give investors instant access to critical insights from SEC filings, press releases, and corporate disclosures. Built to streamline small-cap and microcap stock research, RedChat analyzes thousands of public company documents and delivers clear, context-rich answers to investor questions in seconds. Instead of manually reviewing lengthy filings, investors can simply ask RedChat about financial results, partnerships, business strategy, or recent announcements and receive precise, source-based summaries. Investors can experience RedChat and start exploring stocks today at www.redchip.com/stocks or www.red.chat.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

CONTACT:
Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]

--END--

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire

L.Holland--TFWP